Immunic (IMUX) Insider Rudick Richard Alan Buys 25,370 Shares
Richard Alan Rudick purchased 25,370 shares of Immunic, Inc. on June 29, boosting his stake in the biotech firm.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rudick Richard Alan bought 25,370 shares of Immunic, Inc. ($IMUX) on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IMUX is down 3.6% after 1 week, down 15.3% after 1 month and down 54.8% to date (from the $15.41 close on Jun 29, 2026).
IMUX
Immunic, Inc.
Key Points
- Richard Alan Rudick bought 25,370 shares of Immunic, Inc. for about $391,851 on June 29, 2026.
- The stock closed at $15.41 on the day of the transaction, showing an increase from the previous close of $10.62.
- Immunic, Inc. has a market cap of approximately $147.8 million and is focused on developing treatments for chronic inflammatory diseases.
Get $IMUX trade alerts by text
We text you when insiders, Congress or big funds trade $IMUX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immunic, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Immunic, Inc.
Richard Alan Rudick bought 25,370 shares of Immunic, Inc. (IMUX) on June 29, 2026, valued at about $391,851 based on the closing price of $15.41. This purchase reflects Rudick's confidence in the company's potential as it continues to develop therapies for chronic inflammatory and autoimmune diseases.
Other Insiders Join the Buying Trend
On the same day, several other insiders also increased their stakes in Immunic. Simona Skerjanec, Barclay Phillips, Tamar Howson, and Joerg Neermann each bought 25,370 shares, while Jon Congleton purchased 50,740 shares. This wave of insider buying signals a strong belief in the company's future prospects.
How IMUX Stock Has Traded
As of June 29, 2026, IMUX shares traded at $15.41, recovering from a recent low of $5.06. The stock is currently well above its 50-day moving average of $14.20, suggesting positive momentum. The shares reached a 52-week high of $17.43 earlier in the year, indicating volatility and investor interest in the biotech sector.
Analysts Set New Price Targets
On September 10, 2026, Wedbush reiterated its "Outperform" rating for IMUX with a price target of $45.00. HC Wainwright & Co. also maintained a "Buy" rating with a target of $22.00. These ratings reflect positive sentiment among analysts regarding Immunic's growth potential.
What IMUX Does
Immunic, Inc. is a biotechnology company based in New York, focusing on developing oral immunology therapies for chronic inflammatory diseases. These recent insider purchases could indicate strong internal confidence in the company's pipeline and future developments.
What's Ahead for IMUX
Investors should keep an eye on the upcoming earnings report scheduled for November 12, 2026. Insider transactions like Rudick's buy provide insight into the management's confidence in the company's future, though this Form 4 filing reflects past activity and may not represent current positions.
Related Filing Alerts
Source: Rudick Richard Alan's Form 4 filing on $IMUX (Jun 29, 2026). Find the original filing: IMUX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts